Compare Cassava Sciences Inc (FLNA) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wynn Resorts, Limited — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Wynn Resorts, Limited trades at $98.57 (market cap $10.07B). The key difference: Wynn Resorts, Limited is far larger — about 189.5× Cassava Sciences Inc's market cap, and Wynn Resorts, Limited pays a 1.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WYNN | |
|---|---|---|
Market Cap | $53.14M | $10.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $133.34 |
52-Week Low | $1.09 | $94.78 |
Enterprise Value | -$33.43M | $20.44B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Wynn Resorts (WYNN) trades at $98.57, up 2.78% today but down 13.4% year-to-date, reflecting mixed performance amid earnings volatility. The stock shows a bearish technical signal with resistance near $110, while fundamentals reveal revenue growth to $7.14B in 2025 but declining net margins to 4.58%. Recent Q1 2026 earnings met expectations at $1.25 EPS, though prior quarters missed estimates. Analyst sentiment remains strongly bullish with a $135 consensus target, but high debt and Macau competition pose risks.
The outlook for Wynn is cautiously optimistic, driven by luxury market recovery and analyst confidence, yet tempered by margin pressure and significant leverage. Investment opportunity lies in potential upside to price targets if execution improves, but risks include geopolitical impacts on international operations and sustained earnings misses. The stock's current valuation at 27.81 P/E requires careful monitoring of quarterly performance against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
